Phathom Pharmaceuticals (PHAT) Share-based Compensation (2019 - 2026)

Phathom Pharmaceuticals (PHAT) has reported Share-based Compensation for 8 consecutive years, with $18.1 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Share-based Compensation rose 118.81% year-over-year to $18.1 million; the TTM figure through Jun 2026 stood at $18.1 million (down 30.74% YoY), while the FY2025 annual figure was $28.7 million, up 19.43% from the prior year.
• Share-based Compensation eased to $18.1 million in Q2 2026 per PHAT's latest filing, from $20.1 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $24.6 million in Q4 2023 and bottomed at $5.5 million in Q1 2025.
• Historically, Share-based Compensation has averaged $8.9 million across 5 years, with a median of $6.4 million in 2022.
• Annual changes were most pronounced in 2023 — Share-based Compensation jumped 269.3% — and 2024, when it plunged 72.8%.
• Phathom Pharmaceuticals' Share-based Compensation stood at $6.7 million in 2022, then surged by 269.3% to $24.6 million in 2023, then sank by 72.8% to $6.7 million in 2024, then retreated by 16.11% to $5.6 million in 2025, then soared by 222.64% to $18.1 million in 2026.
• Business Quant data shows PHAT's Share-based Compensation at $18.1 million in Q2 2026, $20.1 million in Q1 2026, and $5.6 million in Q4 2025.